Cryo-Cell International Inc. - 10-Q Summary (Period Ended August 31, 2011)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for Cryo-Cell International, Inc., a smaller reporting company engaged in cellular processing and cryogenic storage of umbilical cord blood (U-Cord) and menstrual stem cells (Céllé). The reporting period covers the three and nine months ended August 31, 2011. The company operates primarily from Oldsmar, Florida, with international licensing agreements.
Key Financial Metrics
| Metric | 9 Months Ended Aug 31, 2011 | 9 Months Ended Aug 31, 2010 |
|---|---|---|
| Total Revenue | $13,481,829 | $13,184,310 |
| Net Loss | $(1,971,568) | $3,121,866 (Income) |
| Operating Loss | $(586,876) | $2,595,847 (Income) |
| Cash and Cash Equivalents | $5,873,490 | $8,369,537 (Nov 30, 2010) |
| Restricted Cash | $2,700,000 | $200,000 (Nov 30, 2010) |
| Net Cash from Operating Activities | $459,741 | $1,703,285 |
| Cost of Sales Margin | 26% of Revenue | 25% of Revenue |
Material Changes vs. Prior Period
- Profitability Reversal: The company shifted from a net income of $3.12 million in the prior year period to a net loss of $1.97 million. This was driven by a 46% increase in Marketing, General, and Administrative (MG&A) expenses.
- Expense Drivers: MG&A expenses rose to $10.18 million (from $6.97 million) due to:
- Approximately $940,000 in costs related to the 2011 Annual Meeting and proxy contest (including $528,000 reimbursed to the Portnoy Group).
- An accrual of approximately $950,000 for severance related to the termination of former CEO Mercedes Walton.
- Increased stock option compensation expense ($407,000 vs. $98,000).
- Write-off of abandoned patents ($208,000).
- Revenue Growth: Total revenue increased 2% year-over-year. Processing and storage fees rose 4% due to a 9% increase in specimens processed, partially offset by a 13% decrease in licensee income due to timing of fees and the absence of a $125,000 up-front fee from Venezuela recorded in the prior year.
- Liquidity Impact: Cash decreased by approximately $2.5 million, primarily due to the funding of a $2.5 million Grantor Trust to escrow potential severance payments following a change in control of the Board of Directors.
Guidance, Outlook, and Risks
- Management Commentary: Following a change in control of the Board of Directors in August 2011, management intends to re-focus efforts on the core U-Cord business while continuing development of Céllé technology. The company anticipates cash on hand and operating cash flows will be sufficient to fund operations for the next 12 months.
- Unusual Items:
- Change in Control: The Portnoy Group won the proxy contest, resulting in a complete change of the Board. Former CEO Mercedes Walton was terminated for cause, though the company has accrued $950,000 for potential severance and intends to contest the claim.
- Accounting Change: The company retrospectively adopted a new accounting principle (ASU 2009-13) regarding revenue recognition for multiple deliverable arrangements, adjusting prior period financials for comparability.
- Risks and Contingencies:
- Legal Proceedings: The company lost a motion to dismiss in a lawsuit against Cord Blood America, Inc. (CBAI) regarding the acquisition of the Mexican licensee; the company does not plan to appeal. A separate complaint for monetary damages (>$75,000) is pending with a trial scheduled for February 2013.
- License Agreements: The Mexican licensee agreement was amended following a termination notice, resulting in a fixed payment stream of $1.86 million over 37 months, reducing future royalty income.
- Valuation Allowance: The company maintains a valuation allowance of $7.57 million against deferred tax assets, indicating it does not believe it is "more likely than not" that future tax benefits will be realized.
Investor Verification Checklist
- Severance Liability: Verify the likelihood of the $950,000 severance accrual for the former CEO being paid, given the "for cause" termination and management's intent to defend against the claim.
- Proxy Contest Costs: Confirm the total one-time costs associated with the 2011 proxy contest and annual meeting to assess the run-rate of future MG&A expenses.
- Liquidity Position: Review the $2.7 million in restricted cash held in the Grantor Trust and determine the conditions under which these funds might be returned to the company or paid out.
- Revenue Recognition: Understand the impact of the retrospective accounting change on the comparability of current revenue figures versus historical data.
- Licensee Stability: Monitor the status of international licensees, particularly the amended agreement in Mexico and the collectability of receivables from foreign affiliates.